Short-lived Stem Cells Fight Brain Tumors -- For a Time

Breindl, Anette
May 2013
BioWorld Today;5/13/2013, Vol. 24 Issue 91, p1
The article discusses research on the use of stem cells to fight brain tumors. It makes reference to the preclinical studies of the investigational new drug application by Karen Aboody and colleagues published in the May 9, 2013 issue of "Science Translational Medicine." It discusses the results of treatment of brain tumors implanted in animals with neural stem cells and potentials of the treatment for human application.


Related Articles

  • Potential role of stem cells in severe spinal cord injury: current perspectives and clinical data. Paspala, Syed A. B.; Vishwakarma, Sandeep K.; Murthy, Tenneti V. R. K.; Rao, Thiriveedi N.; Khan, Aleem A. // Stem Cells & Cloning: Advances & Applications;2012 Part 2, Vol. 5, p15 

    Stem cell transplantation for spinal cord injury (SCI) along with new pharmacotherapy research offers the potential to restore function and ease the associated social and economic burden in the years ahead. Various sources of stem cells have been used in the treatment of SCI, but the most...

  • A novel method to derive and expand mice neural stem cells efficiently without neuro-sphere formation. Zhi-Zhao Ma; Lin Fan; Jun-Ling Huang; Xiao-Jing Pan // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 8, p12834 

    Neural stem cells (NSCs) are multi-potent stem cells able to self-renew and generate immature and differentiated cell populations by asymmetric division. The NSCs are of considerable interest for cell replacement in neuro-degenerative diseases. NSCs are usually identified and expanded by their...

  • Intravenous Implanted Neural Stem Cells Migrate to Injury Site, Reduce Infarct Volume, and Improve Behavior after Cerebral Ischemia. Chiung-Chyi Shen; Chen-Huan Lin; Yi-Chin Yang; Ming-Tsang Chiao; Wen-Yu Cheng; Jiunn-Liang Ko // Current Neurovascular Research;Aug2010, Vol. 7 Issue 3, p167 

    No abstract available.

  • Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease. Master, Zubin; McLeod, Marcus; Mendez, Ivar // Journal of Medical Ethics;Mar2007, Vol. 33 Issue 3, p169 

    Stem cells are likely to be used as an alternate source of biological material for neural transplantation to treat Parkinson's disease in the not too distant future. Among the several ethical criteria that must be fulfilled before proceeding with clinical research, a favourable benefit to risk...

  • Neural Stem Cells as a Therapeutic Approach for Amyotrophic Lateral Sclerosis. Ferraiuolo, Laura; Frakes, Ashley; Kaspar, Brian K // Molecular Therapy;Mar2013, Vol. 21 Issue 3, p503 

    The article offers the authors' insights on the therapeutic use of neural stem cells (NSCs) for amyotrophic lateral sclerosis (ALS). The authors feature a report written by Y. D. Teng and colleagues on successful transplantation of NSCs to a mouse model of ALS to prolong its life. They mentions...

  • Stem cells to kill cancer.  // BioSpectrum;Dec2014, Vol. 12 Issue 12, p64 

    The article focuses on the study led by Indian-origin scientist Dr. Khalid Shah which shows that stem cells can kill brain tumours by delivering therapeutic toxins.

  • Stem Cell Therapy Extends Incubation and Survival Time in Prion-Infected Mice in a Time Window-Dependant Manner. Relaño-Ginés, Aroa; Lehmann, Sylvain; Bencsik, Anna; Eugenia Herva, María; María Torres, Juan; Crozet, Carole A. // Journal of Infectious Diseases;10/1/2011, Vol. 204 Issue 7, p1038 

    Prion diseases, which are mostly represented in humans by Creutzfeldt-Jakob disease, are transmissible neurodegenerative disorders characterized by vacuolization and neuronal loss, as well as by the accumulation of an abnormal form of the prion protein. These disorders have yet no effective...

  • Use of genetically engineered stem cells for glioma therapy (Review). HIROKI NAMBA; HIROSHI KAWAJI; TOMOHIRO YAMASAKI // Oncology Letters;Jan2016, Vol. 11 Issue 1, p9 

    Glioblastoma, the most common and most malignant type of primary brain tumor, is associated with poor prognosis, even when treated using combined therapies, including surgery followed by concomitant radiotherapy with temozolomide-based chemotherapy. The invasive nature of this type of tumor is a...

  • PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Chearwae, W.; Bright, J. J. // British Journal of Cancer;12/16/2008, Vol. 99 Issue 12, p2044 

    Brain tumour stem cells (BTSCs) are a small population of cells that has self-renewal, transplantation, multidrug resistance and recurrence properties, thus remain novel therapeutic target for brain tumour. Recent studies have shown that peroxisome proliferator-activated receptor gamma...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics